{"name":"Tyligand Bioscience (Shanghai) Limited","slug":"tyligand-bioscience-shanghai-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Phase II-solid tumors or lymphomas","genericName":"Phase II-solid tumors or lymphomas","slug":"phase-ii-solid-tumors-or-lymphomas","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Phase II-solid tumors or lymphomas","genericName":"Phase II-solid tumors or lymphomas","slug":"phase-ii-solid-tumors-or-lymphomas","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1wY04wUHpRWFVrTnBfOVBoSnVjTkRxMUhQT056dnR2bkhwNWhJaGk0a0ViZ1M1anFXT0pSY0lLNXItc0FWS1RIMkpuc1RxUlFJSkJpS2pyY19SaVhJaHlMallkeGRscU1lOE1N?oc=5","date":"2025-02-13","type":"trial","source":"Wiley Online Library","summary":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma - Wiley Online Library","headline":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUURzNWJXQ003bzRRVHU1U3F6ckVOYjFDUU5UT3dYVVdvWHRUYjE0R0ZTV29ybGNQMHppc3phOHJJRVlYaDBfaXozWUFqYjMyTEpWejhUeTZWSGlKSlNpd2RFUEo0eVYzOE5PQ3RxSmVETjZWTktydGc5MDI0RmpMNU1wYXFSMXoyS2pGcnRXY1JvYk1CVzJNa2RWVmY2OGd2S3gtVW1RZGNlZ0dzdlBoX2VoWmJ5ZVRWMGFBQ1BwcnlFRFFKUVZoR2YydzBmSENlQV9rQ25lLXpBMGNHZkJGb1o1WmNQeEl0eE1kSW5jeE1WeThwcVVEcWVR?oc=5","date":"2021-08-25","type":"pipeline","source":"GlobeNewswire","summary":"Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone - GlobeNewswire","headline":"Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}